We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Name | Symbol | Market | Type |
|---|---|---|---|
| Daiichi Sankyo Company Ltd (PK) | USOTC:DSNKY | OTCMarkets | Depository Receipt |
| Price Change | % Change | Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -1.68 | -4.64% | 34.49 | 34.32 | 34.49 | 35.34 | 34.34 | 34.345 | 30,966 | 15:10:06 |
From May 2021 to May 2024
By Michael Susin
AstraZeneca PLC said on Thursday that its metastatic breast cancer treatment Enhertu has been approved for use in the U.S.
The Anglo-Swedish pharma giant said Enhertu will be used in patients with breast cancer that were treated with a prior treatment and have developed disease recurrence during or within six months of completing therapy.
The company said clinical studies showed that the treatment has reduced the risk of disease progression or death by 72% when compared with other treatment.
Enhertu its a jointly treatment developed and commercialized by AstraZenecaa and Daiichi Sankyo Co.
Astrazeneca said regulatory applications are currently under review in Europe, Japan and several other countries.
Write to Michael Susin at michael.susin@wsj.com
(END) Dow Jones Newswires
May 05, 2022 02:48 ET (06:48 GMT)
Copyright (c) 2022 Dow Jones & Company, Inc.
1 Year Daiichi Sankyo (PK) Chart |
1 Month Daiichi Sankyo (PK) Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
